Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.
about
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseMetabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic aminesCYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studiesToward a new philosophy of preventive nutrition: from a reductionist to a holistic paradigm to improve nutritional recommendations.Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.Investigation of the major cytochrome P450 1A2 genetic variant in a healthy Tibetan population in China.Role of genetic & environment risk factors in the aetiology of colorectal cancer in Malaysia.Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.Genetic variation in melatonin pathway enzymes in children with autism spectrum disorder and comorbid sleep onset delay.quantitative assessment of the influence of cytochrome P450 1A2 gene polymorphism and colorectal cancer riskStructure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study.Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction.CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.Caffeinated coffee, decaffeinated coffee and endometrial cancer risk: a prospective cohort study among US postmenopausal women.Melatonin in Children with Autism Spectrum Disorders: How Does the Evidence Fit Together?Lack of association between polymorphisms in the CYP1A2 gene and risk of cancer: evidence from meta-analyses.PharmGKB summary: very important pharmacogene information for CYP1A2.Coffee, caffeine-related genes, and Parkinson's disease: a case-control studyPolymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk.Caffeine Cytochrome P450 1A2 Metabolic Phenotype Does Not Predict the Metabolism of Heterocyclic Aromatic Amines in Humans.Polymorphisms in carcinogen metabolism enzymes, fish intake, and risk of prostate cancer4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS Human Relevance Framework for Analysis of a cancer mode of action for humans.Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation.Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancerMeat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk.Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.The impact of NAT2 acetylator genotype on mutagenesis and DNA adducts from 2-amino-9H-pyrido[2,3-b]indole.PhRMA white paper on ADME pharmacogenomics.Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancerAssessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake.Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial.Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk.Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects.Factors affecting interindividual differences in clozapine response: a review and case report.Pharmacogenomics of third-generation aromatase inhibitors.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.Association between the CYP1A2-164 A/C polymorphism and colorectal cancer susceptibility: a meta-analysis.
P2860
Q28252209-34219143-C8D6-4A84-B49D-8412EBF63F59Q28391158-0D50CD95-6D3D-4DC2-A38A-DF96CFBBE3EDQ28392197-890810E1-CA93-4EF9-AAF1-1109986B1511Q30364674-E68E7482-E8EA-4003-A005-DC57ADEDA8E9Q33289676-E7659E9C-F759-4D62-9177-466F2D5B374CQ33828034-39F6A3BF-E4C3-4222-8315-D9F6EE9E5A58Q34186137-A62713B8-B071-4CED-AAE4-5E9E966FDEAAQ34311814-6181A3F5-0B6E-4B18-B73C-E16146DAE0A0Q34430684-86DCFF10-2872-46E8-AAB6-CF7E12DEC234Q34949682-83F95C55-7B84-45E4-A403-69788D0238B5Q35015993-75B7557E-A613-4D77-93A0-ABEA92FD8E90Q35199390-E7C24CA6-BFB4-47CB-8001-4C1D4E574E49Q35443937-8C9C9D4A-6D73-45BF-AD54-C9CDDEA0C3E0Q35647173-91CE1AB5-D48B-4F7E-82FE-F515E8431DBBQ35671114-B89365B4-9AF8-41B0-B3B4-9F50A0125D51Q35774172-4E220C54-B2D9-4BB3-9E49-DC5C364A0C14Q35920271-97654975-388F-4EDC-80F5-06F48770BC5BQ35940452-030CA815-12D7-44B5-B3A6-4FB77FCD1701Q36011013-55C7FA9C-0DB5-438A-BAC7-828335E3EF63Q36038263-F8FEB3BC-3CC1-4A50-8613-EFC52AE1A5C2Q36063995-D3C95E0D-A213-4752-89E6-F3BB192F975EQ36401990-CB5B7AEB-8ED0-458A-BF38-2F1C45E658E5Q36659782-DE3E9C11-290E-40E7-A9BD-F25BDA88FF85Q36662879-0DCFA840-237B-424F-A9B3-9367AB17775AQ36743654-0F394B23-9767-4E70-AA6F-DA1589ECC6F9Q36948550-8BD9B7EF-46B8-4A80-A634-EDE1C1FDF52FQ37157901-57946492-90A9-4B82-B749-786039485FC6Q37168876-69F95ACC-2EFB-44C2-9C78-813A1D1F78D5Q37182212-8A177889-9D0D-4B47-82E9-E3EF6AC4F338Q37286958-B94DB6AA-00F0-4C7A-8D7D-6C861FA955B3Q37315406-54A3D55B-2783-4824-A57D-1546DE88F92EQ37378059-A749EFBE-F813-489A-9E54-A960FF8E34DAQ37442320-62A010B1-491A-4EAD-B110-972BC261F927Q37444361-BBADFBCA-DCAD-4086-88E4-B35702F0E921Q37669797-F9042D33-CD53-4139-A477-8F920C3AC381Q37860249-11A9AAB2-5C46-43EC-8C63-22D09D9905DFQ38010777-AC912A83-2321-43BD-A288-2B4B0C7A69B4Q38103885-EDCAA84C-432A-442B-BF93-12CDF21094C4Q38180095-34312BC2-7657-44B9-B020-EF5F1B72F530Q38186992-21121C54-813A-4C58-9B92-B05536FC47BF
P2860
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@en
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@en-gb
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@nl
type
label
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@en
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@en-gb
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@nl
prefLabel
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@en
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@en-gb
Polymorphisms in the cytochrom ...... luence on caffeine metabolism.
@nl
P2093
P2860
P50
P1476
Polymorphisms in the cytochrom ...... fluence on caffeine metabolism
@en
P2093
Christoph Sachse
Colorectal Cancer Study Group
Jenna Scollay
Nigel J Gooderham
R Colin Garner
Tracy J Lightfoot
Upinder Bhambra
P2860
P356
10.1046/J.1365-2125.2003.01733.X
P407
P577
2003-01-01T00:00:00Z